Keolium 100 IR/ 300 IR comprimidos sublinguais Tratamento de iniciação Keollum 300 IR comprimidos subllnguals Tratamento de continuação Keollum 300 IR comprimidos subllnguals Tratamento de continuação ORALAIR 100 IR & 300 IR compresse sublinguali Inizio del trattamento ORALAIR 100 IR & 300 IR poliežuvinės tabletės ORALAIR 100 IR & 300 IR Sublingualtabletten ORALAIR 100 IR & 300 IR Sublingualtabletten Einleitungsbehandlung Oralair 100 IR & 300 IR sublingválne tablety Iniciacná liecba ORALAIR 100 IR & 300 IR tabletes lietošanai zem mēles Ārstēšanas uzsākšanai ORALAIR 100 IR & 300 IR tabletten voor sublinguaal gebruik Startbehandeling ORALAIR 100 IR & 300 IR tabletten voor sublinguaal gebruik Startbehandeling ORALAIR 100 IR & 300 IR, 100 IR / 300 IR, tabletki podjezykowe Leczenie wstepne
DE/H/1930/001
5426440
STALLERGENES
PT
DE/1930/002
5426424
STALLERGENES
PT
DE/H/1930/002
5426432
STALLERGENES
PT
DE/H/1930/001
039857014
STALLERGENES
IT
DE/H/1930/001
LT/1/10/2024/001
STALLERGENES
LT
DE/1930/001/MR
BE364515
STALLERGENES
BE
DE/1930/001
PEI.H.03450.01.1
STALLERGENES
DE
DE/1930/001
59/0853/09-S
STALLERGENES
SK
DE/H/1930/001
10-0048
STALLERGENES
LV
DE/H/1930/001
RVG 105376
STALLERGENES
NL
DE/1930/001
BE364515
STALLERGENES
BE
DE/H/1930/001
16729
STALLERGENES
PL
L is t of nationally authorised medicinal products E MA/596847/2017
P age 2 /6
Product Name (in
MRP/DCP Authorisation
National Authorisation
MAH of product in the
Member State where
authorisation country)
number
Number
member state
product is authorised
ORALAIR 100 IR & 300 IR, comprimés sublinguaux Traitement d’initiation ORALAIR 100 IR & 300 IR, comprimés sublinguaux Traitement d'initiation ORALAIR 100 IR & 300 IR, comprimés sublinguaux Traitement d'initiation ORALAIR 100 IR & 300 IR, keelealused tabletid Ravi alustamine ORALAIR 100 IR + 300 IR Sublingualtabletten Einleitungsbehandlung ORALAIR 100 IR és 300 IR nyelvalatti tabletta Kezdo kezelés ORALAIR 100 IR in 300 IR podjezične tablete začetno zdravljenje ORALAIR 100 IR&300 IR, sublingvální tablety Úvodní lécba ORALAIR 100IR & 300IR comprimate sublinguale Tratament de initiere Oralair 100IR & 300IR sublingual tablets Initiation treatment ORALAIR 300 IR compresse sublinguali Prosecuzione del trattamento
DE/H/1930/001
2010050081
STALLERGENES
LU
DE/1930/001
BE364515
STALLERGENES
BE
DE/1930/001
3400936895164
STALLERGENES
FR
DE/1930/001
672810
STALLERGENES
EE
DE/1930/001
2-00361
STALLERGENES
AT
DE/H/1930/001
OGYI-T-21527/01
STALLERGENES
HU
DE/H/1930/001
5363-I-421/14
STALLERGENES
SI
DE/H/1930/001
59/160/10-C
STALLERGENES
CZ
DE/H/1930/002
5858/2013/01
STALLERGENES
RO
DE/H/1930/001
PA2113/001/001
STALLERGENES
IE
DE/H/1930/002
039857026
STALLERGENES
IT
L is t of nationally authorised medicinal products E MA/596847/2017
P age 3 /6
Product Name (in
MRP/DCP Authorisation
National Authorisation
MAH of product in the
Member State where
authorisation country)
number
Number
member state
product is authorised
ORALAIR 300 IR compresse sublinguali Prosecuzione del trattamento ORALAIR 300 IR comprimate sublinguale Tratament de continuare ORALAIR 300 IR comprimate sublinguale Tratament de continuare ORALAIR 300 IR comprimidos sublinguales Tratamiento de continuación ORALAIR 300 IR nyelvalatti tabletta Fenntartó kezelés ORALAIR 300 IR nyelvalatti tabletta Fenntartó kezelés ORALAIR 300 IR podjezicne tablete nadaljevalno zdravljenje ORALAIR 300 IR podjezicne tablete nadaljevalno zdravljenje ORALAIR 300 IR poliežuvinės tabletės ORALAIR 300 IR poliežuvinės tabletės Oralair 300 IR sublingual tablets C ontinuation treatment ORALAIR 300 IR Sublingualtabletten
DE/H/1930/002
039857038
STALLERGENES
IT
DE/H/1930/002
5859/2013/01
STALLERGENES
RO
DE/1930/002
5859/2013/02
STALLERGENES
RO
DE/1930/002
71954
STALLERGENES
ES
DE/H/1930/002
OGYI-T-21527/02
STALLERGENES
HU
DE/1930/002
OGYI-T-21527/03
STALLERGENES
HU
DE/H/1930/002
5363-I-422/14
STALLERGENES
SI
DE/H/1930/002
5363-I-423/14
STALLERGENES
SI
DE/1930/002
LT/1/10/2024/003
STALLERGENES
LT
DE/1930/002
LT/1/10/2024/002
STALLERGENES
LT
DE/H/1930/002
PA2113/001/002
STALLERGENES
IE
DE/1930/002/MR
BE364524
STALLERGENES
BE
L is t of nationally authorised medicinal products E MA/596847/2017
P age 4 /6
Product Name (in
MRP/DCP Authorisation
National Authorisation
MAH of product in the
Member State where
authorisation country)
number
Number
member state
product is authorised
ORALAIR 300 IR Sublingualtabletten Fortsetzungsbehandlung ORALAIR 300 IR Sublingualtabletten Fortsetzungsbehandlung Oralair 300 IR sublingválne tablety Pokracovanie liecby ORALAIR 300 IR tabletes lietošanai zem mēles Ārstēšanas turpināšanai ORALAIR 300 IR tabletten voor sublinguaal gebruik Vervolgbehandeling ORALAIR 300 IR tabletten voor sublinguaal gebruik Vervolgbehandeling ORALAIR 300 IR, comprimés sublinguaux Traitement d’entretien ORALAIR 300 IR, comprimés sublinguaux Traitement d’entretien ORALAIR 300 IR, comprimés sublinguaux Traitement d’entretien ORALAIR 300 IR, comprimés sublinguaux Traitement d'entretien ORALAIR 300 IR, comprimés sublinguaux Traitement d'entretien ORALAIR 300 IR, keelealused tabletid Jätkuravi
DE/H/1930/002
2 – 00362
STALLERGENES
AT
DE/1930/002
PEI.H.03450.02.1
STALLERGENES
DE
DE/1930/002
59/0854/09-S
STALLERGENES
SK
DE/H/1930/002
10-0049
STALLERGENES
LV
DE/H/1930/002
BE364524
STALLERGENES
BE
DE/H/1930/002
RVG 105380
STALLERGENES
NL
DE/H/1930/002
BE364524
STALLERGENES
BE
DE/H/1930/002
2010050082
STALLERGENES
LU
DE/H/1930/002
2010050082
STALLERGENES
LU
DE/H/1930/002
34009 368 952 2 5
STALLERGENES
FR
DE/1930/002
3400936895393
STALLERGENES
FR
DE/H/1930/002
672910
STALLERGENES
EE
L is t of nationally authorised medicinal products E MA/596847/2017
P age 5 /6
Product Name (in
MRP/DCP Authorisation
National Authorisation
MAH of product in the
Member State where
authorisation country)
number
Number
member state
product is authorised
ORALAIR 300 IR, sublingvální tablety Udržovací lécba ORALAIR 300 IR, tabletki podjezykowe Kontynuacja leczenia ORALAIR INIC IO 100 IR y 300 IR comprimidos sublinguales Tratamiento de inicio ОРАЛАИР 100 IR и 300 IR сублингвални таблетки Първоначално лечение ОРАЛАИР 300 IR сублингваЛIIИ таблетки Прод ължава що лечение
DE/H/1930/002
59/159/10-C
STALLERGENES
CZ
DE/H/1930/002
16730
STALLERGENES
PL
DE/1930/001
71953
STALLERGENES
ES
DE/1930/001
20100376
STALLERGENES
BG
DE/1930/002
20100374
STALLERGENES
BG
L is t of nationally authorised medicinal products E MA/596847/2017
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).
maximises the chances of a successful marketing authorisation. ... marketing authorisation. ⢠inclusion in the public SME ... E-mail [email protected]. Website ...
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs â meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju
Feb 7, 2017 - Add an existing Tag to a specific Term . ...... This service creates an email body (text/html) of a user's notification data, a notification is based on.
Feb 9, 2018 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. â¢. Product
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri
Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply). (possible) lack of ...
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina SchüÃler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g
Jun 14, 2018 - Page 2/26. Product Name (in authorisation country). MRP/DCP Authorisation number. National Authorisation. Number. MAH of product in the.
Oct 26, 2017 - Injektionssuspension in einer Fertigspritze. Influenza-Impfstoff. (Spaltimpfstoff, inaktiviert, in Zellkulturen hergestellt) not available. BE393556. NANOTHERAPEUTICS. BOHUMIL, S.R.O.. BE. Preflucel injektionsvätska, suspension i för
March 2016 a joint database drug utilisation final study report to the European .... With regards to prescription of CPA/EE for contraceptive management, ...
For a list of RSS readers please refer to our RSS guide and follow the instructions ..... PCWP and HCPWP joint meeting: Workshop on social media - Sep 2016.
Jul 14, 2016 - Stem cell-based products for veterinary use: specific ... potentially delay time to rejection providing a window of therapeutic benefit but limiting ...
